Items Tagged ‘Waldenström’s macroglobulinemia’

February 24th, 2015

FDA Approves New Indication for Ibrutinib in Waldenström’s Macroglobulinemia


The US Food and Drug Administration (FDA) today expanded the approved use of Imbruvica® (ibrutinib) for patients with Waldenström’s macroglobulinemia, a rare type of B-cell lymphoma. Imbruvica® is the first therapy indicated specifically for Waldenström’s macroglobulinemia and previously received Breakthrough Therapy designation for this use. A type of non-Hodgkin lymphoma, Waldenström’s macroglobulinemia usually gets worse […]

View full entry

Tags: b-cell lymphoma, Breakthrough Therapy, ibrutinib, imbruvica, Indolent/Low Grade Non-Hodgkin's Lymphoma, News, Non-Hodgkin's Lymphoma, Waldenström’s macroglobulinemia